Fred Hutchinson Cancer Research Center: Financial Literacy for Cancer Patients

Work presented by Veena Shankaran, MD, MS, associate professor, Division of Medical Oncology, University of Washington and associate member, Clinical Research Division, Fred Hutchinson Cancer Research Center, at the the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Related Videos

Related Content

Advertisement

June 13th 2025

Is the Employer Health Care Tax Exclusion Safe? Kerris Willis Shares Insight From American Benefits Council

Giuliana Grossi

While the tax exclusion for employer-sponsored health care was not included in the House-passed reconciliation bill, it remains a revenue target for Congress, risking inclusion in the Senate's version.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

June 13th 2025

COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results

Christina Mattina

A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

June 12th 2025

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

Giuliana Grossi

The FDA approved mitomycin intravesical solution (Zusduri) for patients with recurrent low-grade intermediate risk non–muscle-invasive bladder cancer (NMIBC).

June 12th 2025

Immunotherapy Timing Does Not Significantly Affect Outcomes in ES-SCLC

Jared Kaltwasser

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small cell lung cancer (ES-SCLC), a study found.

Related Content

Advertisement

June 13th 2025

Is the Employer Health Care Tax Exclusion Safe? Kerris Willis Shares Insight From American Benefits Council

Giuliana Grossi

While the tax exclusion for employer-sponsored health care was not included in the House-passed reconciliation bill, it remains a revenue target for Congress, risking inclusion in the Senate's version.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

June 13th 2025

COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results

Christina Mattina

A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

June 12th 2025

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

Giuliana Grossi

The FDA approved mitomycin intravesical solution (Zusduri) for patients with recurrent low-grade intermediate risk non–muscle-invasive bladder cancer (NMIBC).

June 12th 2025

Immunotherapy Timing Does Not Significantly Affect Outcomes in ES-SCLC

Jared Kaltwasser

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small cell lung cancer (ES-SCLC), a study found.